“What these new treatments have been able to achieve is to really impact the life expectancy of men with advanced and metastatic prostate cancer, even if they were diagnosed with quite significant burden of disease. With these new treatments we are able to improve, on average, the life expectancy by a few years, at least, and certainly these treatments are not something that we would have had to offer five years ago.” ~ Dr. Sebastien Hotte
To learn more about mHSPC please speak with your healthcare provider.
This program was brought to you by one of Canada’s leading research-based pharmaceutical companies.
Dr. Sebastien Hotte
Associate Professor, Dept of Oncology, McMaster University
Oncologist, Juravinski Cancer Centre
Mark Woodfield, age 52
Diagnosed mHSPC at Age 50